Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Thursday, 31'st Jul 2025
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
10:01am, Wednesday, 30'th Jul 2025
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
06:51pm, Monday, 28'th Jul 2025
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.
Why Gilead Sciences Stock Slipped Today
04:32pm, Monday, 28'th Jul 2025
Prominent pharmaceutical company Gilead Sciences (GILD -2.76%) wasn't prominent in the minds of investors on Monday. Following media reports that a key federal agency was contemplating a move that mig
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Sunday, 27'th Jul 2025
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advise
Why Gilead Sciences Stock Just Popped
01:37pm, Friday, 25'th Jul 2025
Biopharmaceuticals stock Gilead Sciences (GILD 2.74%) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded the shares to a buy rating and slapped a $133 price target on the $116 stock
Final Trades: Gilead, Blackstone, Disney and Visa
01:25pm, Friday, 25'th Jul 2025
The Investment Committee give you their top stocks to watch for the second half.
Calls of the Day: Gilead, Chipotle and P&G
01:18pm, Friday, 25'th Jul 2025
The Investment Committee debate the latest Calls of the Day.
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales
12:12pm, Friday, 25'th Jul 2025
In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s GILD Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adu
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
10:41am, Friday, 25'th Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EU regulator backs Gilead's twice-yearly injection for HIV prevention
03:03am, Friday, 25'th Jul 2025
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said on F
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
04:05pm, Thursday, 24'th Jul 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2025 financial results and guidance will be released on Thursday, August
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
07:01pm, Tuesday, 22'nd Jul 2025
Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Tuesday, 22'nd Jul 2025
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised
